MediPharm Labs Investor Dashboard

Company Overview:

Founded in 2015, MediPharm Labs has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the ACMPR without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to produce purified, pharmaceutical-like cannabis oil and concentrates for advanced derivative products. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream extraction methodologies and purpose-built facilities to deliver pure, safe and precisely-dosed cannabis products to patients and consumers. MediPharm Labs’ private label program is a high margin business for the Company, whereby it opportunistically procures dry cannabis flower and trim from its numerous product supply partners, to produce proprietary cannabis oil concentrate products for resale globally on a private label basis.

[stock_market_chart symbol=”LABS.v” range=”1y” settings='{“primaryChartType”:”smoothedLine”,”width”:”100%”,”height”:”350px”,”marginTop”:0,”marginBottom”:0,”marginLeft”:10,”marginRight”:10,”primaryPanelTitle”:”Price”,”secondaryPanelTitle”:”Volume”,”fontSize”:13,”color”:”#383838″,”primaryLineColor”:”#000″,”primaryLineColorAlpha”:0.15,”secondaryLineColor”:”#000″,”secondaryLineColorAlpha”:0.15,”backgroundColor”:”#fff”,”gridColor”:”#e0e0e0″,”gridAlpha”:0.8,”cursorColor”:”#ba0000″,”cursorAlpha”:0.8,”scrollbarBackgroundColor”:”#fff”,”scrollbarSelectedBackgroundColor”:”#000″,”scrollbarGraphFillColor”:”#000″,”scrollbarSelectedGraphFillColor”:”#000″,”primaryLineThickness”:0,”secondaryLineThickness”:0,”gridThickness”:0,”precision”:2,”thousandsSeparator”:”,”,”decimalSeparator”:”.”,”usePrefixes”:false,”mouseWheelZoomEnabled”:false,”cursorEnabled”:false,”exportEnabled”:false,”scrollbarEnabled”:false,”legendEnabled”:false,”periods”:”1W,1M,6M,YTD,1Y,ALL”,”defaultPeriod”:”1y”}’]

Key Share Information:

Key Balance Sheet Information (in Millions $CAD):

		CYQ4'17	CYQ1'18	CYQ2'18	CYQ3'18	CYQ4'18	CYQ1'19	CYQ2'19
Cash		0.36	0.52	0.51	0.46	7.85	8.40	72.72
Biological Assets
Inventory						9.40	22.05	42.42
Total Assets		0.38	0.53	0.51	0.46	42.73	70.14	174.32
Net Tangible Assets		0.38	0.53	0.51	0.46	42.73	70.14	174.32
Intangibles/Goodwill
Total Liabilities		0.01	0.01	0.01	0.03	14.89	35.75	53.20

Key Operating Items (Quarterly in Millions $CAD):

		CYQ4'17	CYQ1'18	CYQ2'18	CYQ3'18	CYQ4'18	CYQ1'19	CYQ2'19
Revenue						$10.20	$21.95	$31.47
Change in Fair Value of Biologial Assets
Gross Margin						$3.97	$6.86	11.31
Marketing and Sales						$1.27	-$0.91	-0.86
Investor Relations
Total Operating Expenses		$0.02	$0.21	$0.01	$0.21	$12.02	-$7.01	-7.08
Operating Cash Flow (Quarterly)			$0.16	-$0.01	-$0.21	-$11.11	-$11.11	-11.11
Investing Cash Flow (Quarterly)			$0.00	$0.00	$0.00	-$14.60	-$14.60	-14.60
Financing Cash Flow (Quarterly)			$0.00	$0.00	$0.16	$31.06	$31.06	31.06

Listing Statement